Image

    Effectiveness and Safety of Baricitinib in Severe Alopecia Areata: 48-Week Results

    Bianca Maria Piraccini, Stephano Cedirian, Francesca Pampaloni … Michela Starace
    Studysummary This real-world study found that baricitinib 4 mg daily was effective in promoting hair regrowth and improving psychological well-being in Italian adults with severe alopecia areata over 48 weeks, with 63.2% of patients achieving significant hair recovery and 9.4% experiencing adverse events.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 15

    1. Real-Life Effectiveness and Safety of Baricitinib in Patients with Severe Alopecia Areata: A 24-Week Italian Study Journal of the European Academy of Dermatology and Venereology · 2024
    2. Assessment of Clinician-Reported Outcome Measures for Alopecia Areata: A Systematic Scoping Review Clinical and Experimental Dermatology · 2024
    3. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib Dermatology and Therapy · 2024
    4. European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2024
    5. Physician and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries Dermatology and therapy · 2023
    6. Alopecia Areata: What's New in the Epidemiology, Comorbidities, and Pathogenesis? Journal of Dermatological Science · 2023
    7. Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data Dermatology and Therapy · 2023
    8. Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials British Journal of Dermatology · 2023
    9. Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials Journal of dermatological treatment · 2023
    10. Baricitinib for the Treatment of Alopecia Areata Drugs · 2023
    11. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    12. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    13. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
    14. Common Causes of Hair Loss: Clinical Manifestations, Trichoscopy, and Therapy Journal of the European Academy of Dermatology and Venereology · 2020
    15. Italian Guidelines in Diagnosis and Treatment of Alopecia Areata Giornale italiano di dermatologia e venereologia · 2019

    Related research 1

    1. Serum Zinc Concentration in Patients With Alopecia Areata Acta dermato-venereologica (Print) · 2023